Orthopedic Oncology

Your Guide to Tenosynovial Giant Cell Tumor (TGCT)

At a Glance

Tenosynovial Giant Cell Tumor (TGCT) is a rare, benign but locally aggressive tumor affecting joints and tendon sheaths. It is driven by a CSF1 gene mutation. Because it can cause severe joint damage, patients should seek care from an orthopedic oncologist or dedicated sarcoma center.

Welcome to the Tenosynovial Giant Cell Tumor (TGCT) patient resource guide. Receiving a rare tumor diagnosis can be overwhelming, especially when it affects your mobility and comes with confusing medical terminology. This guide is designed to translate the complex science of TGCT into clear, actionable information so you can make informed decisions about your care.

Tenosynovial Giant Cell Tumor (TGCT) is a rare, typically benign condition that affects the lining of joints, bursae, and tendon sheaths ^[1]. While it does not spread to other organs like a typical cancer, it can be “locally aggressive,” meaning it can cause significant damage to the joint if not properly managed ^[2].

Because TGCT is rare, your local doctors may have limited experience with it. The goal of this guide is to equip you with the knowledge you need to advocate for yourself, understand your specific subtype, and assemble a care team with the right expertise.

How to Use This Guide

This resource is broken down into specific topics based on where you are in your journey. You can read it straight through or jump to the sections most relevant to your current situation:

Understanding Tenosynovial Giant Cell Tumor (TGCT): Basics and Terminology

Learn the basics of Tenosynovial Giant Cell Tumor (TGCT). Understand older terms like PVNS, localized vs. diffuse types, and what your diagnosis means.

Symptoms, Imaging, and Pathology of TGCT

Learn about Tenosynovial Giant Cell Tumor (TGCT) diagnosis. Understand common symptoms, why MRI is the gold standard, and how to read your pathology report.

Localized vs. Diffuse TGCT: Understanding Your Subtype

Learn the differences between localized and diffuse tenosynovial giant cell tumor (TGCT). Understand how your specific subtype impacts treatment and prognosis.

The Biology of TGCT: The CSF1 Gene Mechanism

Learn the biology behind Tenosynovial Giant Cell Tumor (TGCT). Understand how the CSF1 gene mutation recruits immune cells and causes joint destruction.

Surgical Options and Orthopedic Oncology for TGCT

Explore surgical treatment options for tenosynovial giant cell tumor (TGCT). Learn about open vs. arthroscopic synovectomy and finding the right oncologist.

Systemic Therapies: CSF1R Inhibitors for Unresectable TGCT

Learn about systemic therapy for unresectable tenosynovial giant cell tumor (TGCT). Understand CSF1R inhibitors like pexidartinib, vimseltinib, and imatinib.

Life with TGCT: Recurrence, Monitoring, and Joint Health

Learn how to manage life after a TGCT diagnosis. Understand MRI monitoring for recurrence, physical therapy strategies, and how to protect your joint health.

You are not alone in this process. Use the questions provided on each page to prepare for your medical appointments and ensure your care team is meeting your needs.

Common questions in this guide

Is Tenosynovial Giant Cell Tumor (TGCT) a type of cancer?

TGCT is a rare, typically benign condition. This means it is not a traditional cancer and does not spread to other organs. However, it can be locally aggressive, meaning it can cause significant damage to the affected joint or tendon if not properly treated.

What kind of doctor should I see for TGCT?

Because TGCT is a rare condition, local doctors may have limited experience with it. It is best treated by specialists at a dedicated sarcoma center, particularly orthopedic oncologists who frequently manage rare bone and soft tissue tumors.

What is the difference between localized and diffuse TGCT?

TGCT is generally classified into two main subtypes: localized and diffuse. Localized TGCT is typically highly curable and contained to a specific area. Diffuse TGCT is more complex, affecting a wider area of the joint lining, and is harder to completely remove.

What causes a Tenosynovial Giant Cell Tumor to form?

TGCT is caused by a genetic glitch involving the CSF1 gene. This specific mutation causes the tissue in your joint to abnormally attract normal immune cells, which then clump together to form the tumor mass.

Curated prompts to bring to your next appointment.

1.Does our hospital use a multidisciplinary team or tumor board to review rare cases like mine?
2.How many patients with TGCT have you personally treated this year?
3.Would my case benefit from a referral to a dedicated sarcoma center?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (2)

1
Tenosynovial Giant-Cell Tumors of the Foot and Ankle: A Critical Analysis Review.
Fraser EJ, Sullivan M, Maclean F, Nesbitt A
JBJS reviews 2017; (5(1)) doi:10.2106/JBJS.RVW.16.00025.
PMID: 28135228
2
Surgical management of 144 diffuse-type TGCT patients in a single institution: A 20-year cohort study.
Spierenburg G, van der Heijden L, Mastboom MJL, et al.
Journal of surgical oncology 2022; (126(6)):1087-1095 doi:10.1002/jso.26991.
PMID: 35736790

This guide is for informational purposes only and does not replace professional medical advice. Because TGCT is rare, always consult an orthopedic oncologist or sarcoma specialist regarding your specific diagnosis and treatment plan.

Get notified when new evidence is published on Tenosynovial giant cell tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents